Clinical Trial Detail

NCT ID NCT03501979
Title Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Alabama at Birmingham
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Trastuzumab + Tucatinib

Age Groups: adult senior

Additional content available in CKB BOOST